Navigation Links
New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
Date:5/9/2008

Phase III trial for ACTEMRA across multiple patient populations, it is an exciting day for RA patients, the science of RA and for Roche."

About the LITHE Trial

The LITHE trial is a three-arm, randomized, double-blind, placebo- controlled study designed to evaluate the safety and efficacy of ACTEMRA (4 mg/kg or 8 mg/kg) combined with methotrexate compared to placebo with methotrexate in RA patients. Patients received either ACTEMRA intravenously every four weeks plus methotrexate weekly or placebo infusions every four weeks plus methotrexate weekly.

The study analyzed patients' response to treatment by measuring structural damage in the joints through X-rays; disease activity was measured through standard assessments such as the ACR score(1), developed by the American College of Rheumatology (ACR). The study also examined improvement in physical function through the Health Assessment Questionnaire (HAQ).

The LITHE trial is one of five Phase III clinical studies designed to evaluate ACTEMRA as a potential new treatment for RA across multiple patient populations. Four of the Phase III trials - OPTION, TOWARD, RADIATE and AMBITION - are completed and have reported meeting their primary study endpoints. Data from all four trials will be presented at the upcoming European Congress of Rheumatology (ECR) held by the European League Against Rheumatism (EULAR) in Paris (June 11-14).

About ACTEMRA(TM) (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody. Studies suggest that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, may reduce inflammation of the joints and relieve certain systemic effects of RA. The extensive clinical development program conducted by Roche includes five clinical studies and has enrolled more than 4,000 patients in 40 countries, including the United States. Four studies are completed and have reported meeting th
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... 2014 Women everywhere know how frustrating a ... uncomfortable, they,re often also embarrassing and have a way ... Support ( http://ph-defense.com ) is a new, over-the-counter product ... homeopathic product. Odor, discharge, and discomfort ... infection. In many cases, the cause of such problems ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2
... 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... to reprise key carfilzomib data presentations that were featured at ... San Diego, California. The teleconference will begin at ... Interested parties may access the teleconference and the presentation that ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, responded today to the allegations raised ... dated December 6, 2011. The Company maintains that the ... "Report") concern matters which have long been disclosed in ...
Cached Medicine Technology:China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 2China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 3China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 4China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 5China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 6
(Date:9/18/2014)... “ Francis Drake Eyewear ” was ... monthly Biz Report, which reviews and features the latest ... host of NewsWatch and technology expert, conducted the review ... can save users hundreds of dollars while still looking ... company creates fashion-forward glasses that are both stylish and ...
(Date:9/18/2014)... 2014 9Lover.com, an internationally well-known designer ... launched a big promotion for its maternity wedding outfits. ... buy discounted maternity wedding dresses on its ... to all global consumers. The company’s development manager believes ... of ladies delighted. The current special offer will last ...
(Date:9/17/2014)... global ablation technologies market is estimated to grow at ... mature markets (such as the U.S., Germany, France, and ... market in 2014, the Asia-Pacific region is poised to ... next five years.Factors such as increasing government initiatives for ... surgical centers, and the rising focus of international and ...
(Date:9/17/2014)... 18, 2014 IntimateRider, an inventor of ... , has announced that it has entered into a ... Mobility LLC. A primary reason for the deal is ... reach is global. About its sales potential, representatives at ... provide you with the latest products on the market ...
(Date:9/17/2014)... 2014 According to Centers for ... an estimated 173,285 sports- and recreation-related traumatic brain injuries, ... a blood test may be available to help doctors ... recovery will take. , In March of this ... found a way to test blood for a protein ...
Breaking Medicine News(10 mins):Health News:NewsWatch Recently Featured the Fashion-Forward Frames “Francis Drake Eyewear” on National Television 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3
... , , , SAN FRANCISCO, ... (ALCMI) today announced the execution of a letter of intent (LOI) ... on molecular diagnostic testing and banking of advanced-stage Lung Cancer tissues. ... http://www.newscom.com/cgi-bin/prnh/20090731/DC55399LOGO ) , , Specific ...
... Survivors of the childhood cancer neuroblastoma are eight times ... to be married, and more likely to have lower ... online July 31 in the Journal of the ... because minimal information exists on the long-term outcomes for ...
... , , TITUSVILLE, N.J., ... approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the ... the first once-monthly, long-acting, injectable atypical antipsychotic approved in the ... will market INVEGA SUSTENNA in the U.S. , , ...
... cells or other health conditions are spread, study finds , ... for low-risk cardiac surgery doesn,t appear to increase one,s chances ... , In the study of 1,062 people who required a ... than 80 percent of the patients were still alive a ...
... , GAINESVILLE, Fla., July 31 Sanofi-aventis US ... facial wrinkles in healthy patients in the USA. It offers results ... 7 years of experience with the product while abroad. It was ... Sanofi-aventis is a leading global pharmaceutical company. The FDA approval ...
... , , PHILADELPHIA, July 31 In ... middle class families still won,t be shielded from the crushing burden of ... erode, according to a study published this week in the New ... and David Grande, M.D., M.P.A, of the University of Pennsylvania,s ...
Cached Medicine News:Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 2Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 3Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 4Health News:Long-term health and social outcomes for neuroblastoma survivors 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 3Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 4Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 5Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 6Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 7Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 9Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 2Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 3Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 4
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: